Other

Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax, Parent

West Pharmaceutical Services Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax, Parent increased by 93.8% to -$100.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 104.0%, from $2.50M to -$100.00K.

Analysis

StatementIncome Statement
SectionOther
First reportedQ2 2024
Last reportedQ1 2026Apr 23, 2026
Metric ID: other_other_comprehensive_income_loss_derivative_exclude_cbbbd9

Historical Data

6 periods
 Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26
Value-$2.60M$6.50M$2.50M$2.50M-$1.60M-$100.00K
QoQ Change—+350.0%-61.5%+0.0%-164.0%+93.8%
YoY Change———+196.2%-124.6%-104.0%
Range-$2.60M – $6.50M
CAGR-92.6%
Avg YoY Growth-10.8%
Median YoY Growth-104.0%

Frequently Asked Questions

What is West Pharmaceutical Services's other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax, parent?
West Pharmaceutical Services (WST) reported other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax, parent of -$100.00K in Q1 2026.
How has West Pharmaceutical Services's other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax, parent changed year-over-year?
West Pharmaceutical Services's other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax, parent decreased by 104.0% year-over-year, from $2.50M to -$100.00K.